Hormonal
Metformin, when added to a hypocaloric diet, significantly improves menstrual status (frequency of cycles) in obese women with PCOS, independent of its lack of additional benefit on insulin sensitivity or visceral fat loss compared to diet alone.
If your PCOS causes irregular or absent periods, adding metformin (850mg twice daily) to your diet plan can help restore regular menstruation. This benefit is distinct from weight loss or insulin improvement, suggesting metformin has specific effects on ovarian function.
Conversely, metformin had significant benefits on the menstrual status.
Why this rating
Randomized controlled trial showing statistically significant improvement in menstrual frequency for the metformin group.
Source
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome
Alessandra Gambineri et al. · Clinical Endocrinology · 2004
DOI 10.1111/j.1365-2265.2004.01973.x
More from this paper
- Hypocaloric dieting is the primary driver for improving insulin sensitivity and reducing hyperinsulinaemia in obese women with PCOS, whereas pharmacological interventions (metformin, flutamide) provide no significant additional benefit for these specific metabolic markers.Good
- Flutamide, when added to a hypocaloric diet, significantly reduces visceral adipose tissue (VAT), androgen levels (androstenedione, DHEA-S, testosterone), and hirsutism scores in obese women with PCOS, independent of weight loss magnitude.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →